等待开盘 09-20 09:30:00 美东时间
+0.620
+0.60%
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.
09-18 02:37
Nuvalent (NASDAQ:NUVL) has announced the pricing of an upsized underwritten public offering of 5 million shares of Class A common stock at $100.00 a share, for an expected gross proceeds to be approxi...
09-17 13:37
CAMBRIDGE, Mass., Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL),...
09-17 10:23
Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in 2025.
09-17 01:44
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
09-17 00:31
Clinical-stage biopharmaceutical company Nuvalent (NASDAQ:NUVL) commenced an underwritten public offering of $350M shares. There can be no assurance as to whether or when the offering may be completed...
09-16 19:22
Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies
09-13 22:00
Nuvalent (NUVL – Research Report) received a Buy rating and a $100.00 price tar...
08-29 16:07
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the
07-22 18:31
Nuvalent (NASDAQ:NUVL) said Henry Pelish has been promoted to chief scientific officer. Pelish had played a vital role in the creation of Nuvalent and had joined as biology lead in 2018. More on Nuval...
07-11 18:45